Do Medibank shares now represent a buying opportunity?

Medibank has said it will not meet any ransom demands, which has seen the hackers begin to publish sensitive stolen customer data.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medibank shares have fallen 21% since the company's October data breach
  • Stake reports its customers have seen this as a buying opportunity
  • At the current share price, the ASX 200 health insurer pays a trailing dividend yield of 4.8%

Medibank Private Ltd (ASX: MPL) shares have come under considerable selling pressure following the company's massive data breach last month.

On 26 October, when the S&P/ASX 200 Index (ASX: XJO) private health insurer emerged from a multi-day trading halt, shares plunged 18.1% over the day.

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Image source: Getty Images

What's going on with the data breach?

In a nutshell, hackers — apparently Russian-based — stole sensitive data from 9.7 million of Medibank's former and current clients. That data includes customer names, dates of birth, addresses, phone numbers and email addresses.

The cybercriminals also accessed health claims data for approximately 480,000 customers.

Earlier this week, the healthcare stock said it would not cave into any ransom demands from the hackers, which saw Medibank shares rise on the day.

The hackers responded by threatening to publish all of the customer data on the dark web. A threat they began to follow through with yesterday.

Do Medibank shares now represent a buying opportunity?

Medibank shares remain down 21% since the company exited its trading halt on 26 October.

So, is it a buying opportunity?

Eliot Hastie, markets analyst at Australian brokerage platform Stake, said that for the platform's clients, the answer looks to be yes.

"Stake customers have seen this as a buying opportunity, with a 1,426% increase in buys last month, suggesting that many are still positive about Medibank's long-term outlook," he said. "In fact, Medibank saw the biggest change from sales to buys of all Australian stocks in October when compared to September."

According to Hastie:

Cyber security incidents often cause an instant hard shock to a share price, but strong companies have generally been able to recover over the long term. That said, there's no way of knowing the true consequences of Medibank's current breach.

There has been a suggestion of a class action lawsuit, which could affect the share price over a longer period, but this situation is still developing, and its impact is yet to be seen.

If you're considering investing in Medibank shares, there's also the potential income stream to keep in mind.

As at yesterday's closing share price of $2.77, Medibank pays a trailing dividend yield of 4.8%, fully franked.

How have Medibank shares been tracking in 2022?

The Medibank share price was in the green, significantly outperforming the ASX 200 over the calendar year, right up until the big selloff on 26 October. That selling now sees Medibank shares down 19% in 2022, compared to an 8% loss posted by the benchmark index.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »